CLMB (calcimembrin; C16orf74; MICT1) - curation notes

Identity

Literature (PubMed search C16orf74 OR calcimembrin OR MICT1, Oct 2026: 17 hits)

Most hits are cancer prognostic / bioinformatic signature papers. Mechanistic papers:

  1. PMID:28881575 (Nakamura lab, 2017, pancreatic cancer). Identified PPP3CA as partner.
    PMID:28881575
    PxIxIT (PDIIIT) dependence: PMID:28881575
    Phospho-T44 dependence: PMID:28881575
  2. PMID:29371937 (2017) cell-permeable DN peptide blocks C16orf74/calcineurin binding,
    suppresses PDAC proliferation. PMID:29371937
  3. PMID:31597713 (2020, abstract only) - homodimer under the cell membrane, binds integrin
    aVb3, Rac1/MMP2 activation in PDAC invasion. Cancer-cell phenotypes; not used for GO.
  4. PMID:41224739 (Cyert lab, Nat Commun 2025; preprint PMID:38798520) - names calcimembrin.
    Lipidation: PMID:41224739
    Composite LxVPxIxIT motif; CLMB is a calcineurin substrate (pThr44):
    PMID:41224739
    Recruitment of calcineurin to membranes: PMID:41224739
    and with the IxIT mutant PMID:41224739
  5. PMID:40355556 (Sul lab, EMBO J 2025) - MICT1 in brown/beige adipocytes. Mostly mouse
    (KO, BAT-specific ablation, overexpression), but human MICT1 also tested in human beige
    adipocytes (adipose MSC derived): PMID:40355556
    Human MICT1 in plasma membrane fraction of HEK293: PMID:40355556
    Mechanism: MICT1 binds PP2B via PxIxIT, limiting PP2B-RIIb interaction / RIIb dephosphorylation,
    prolonging PKA activity. G2A (non-myristoylated) MICT1 is inactive.

Interpretation